Q/C Technologies, Inc. (QCLS) — DEF 14A Filings
All DEF 14A filings from Q/C Technologies, Inc.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (4)
-
QCLS Seeks Shareholder Nod for Dilutive Issuances, Reverse Split
— Oct 20, 2025 Risk: high
Q/C Technologies, Inc. (QCLS) is holding a Special Meeting on November 10, 2025, to address critical financial and corporate governance matters. The company see -
TNF Pharmaceuticals Files 2024 DEF 14A
— Apr 21, 2025 Risk: medium
TNF Pharmaceuticals, Inc. filed its DEF 14A on April 21, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and corpo -
TNF Pharmaceuticals Files Definitive Proxy Statement
— Nov 1, 2024 Risk: low
TNF Pharmaceuticals, Inc. filed a definitive proxy statement (DEF 14A) on November 1, 2024. The filing relates to the company's proxy materials for its sharehol -
MyMD Pharmaceuticals Files Definitive Proxy Statement
— Jul 1, 2024 Risk: low
MyMD Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEF 14A) on July 1, 2024. The filing concerns the company's proxy materials, which are used to so
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX